Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMatthew Spector

About this trial

Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Scheduled to undergo hemi thyroidectomy or total thyroidectomy for thyroid disease, including neoplasm

Must be a minimum of 18 years old or older

Must be able to give documented informed consent to participate in this study

Must be a surgical candidate according to standard of care practices, as determined by the clinical judgement of the investigator

Disqualifiers

Previous history of surgery and/or radiation to the head, neck, or shoulder

Abnormal cardiac rhythm not controlled with medication

The patient has a history of drug-related anaphylactic or severe allergic reactions (CTCAE grade 3+), at the discretion of the treating investigator

Presence or history of any hypersensitivity to bevonescein (or fluorescein) or its excipients that, in the judgment of the investigator, places the patient at increased risk for adverse effects

Trial design

Design model

Single group

Treatments tested in this trial

  • Bevonescein (ALM 488) Infusion

    Drug

    Bevonescein is a synthetic peptide of 17 amino acids conjugated to a fluorescein derivative (5-carboxyfluorescein \[FAM\]) and can be visualized using instruments suitable for visualizing fluorescein. Bevonescein selectively binds to extracellular matrix of nerve tissue, increasing nerve visibility and enhancing structure delineation of nerve tissue, potentially reducing the time needed for surgeons to identify nerve tissue and reducing likelihood of nerve injury during thyroidectomy surgery.

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: Bevonescein (ALM 488) InfusionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Voice Handicap Index (VHI) scores

Mean change in Voice Handicap Index (VHI) scores pre-operatively and post-operatively. Voice Handicap Index (VHI) is a 30-item self-administered questionnaire divided equally into three subscales designed to measure a patient's perceived handicap related to their voice disorder across functional, physical, and emotional domains. Functional (F) subscale (10 items) evaluates how voice problems affect daily activities, work, and social interactions (difficulty being understood on the phone or professional duty limitations). Physical (P) subscale (10 items) addresses physical sensations or characteristics of the voice problem (vocal fatigue, strain, or pitch changes). Emotional (E) subscale (10 items) assesses the emotional impact of a voice disorder (frustration, embarrassment, or anxiety) related to voice use. Item scores range from 0 (never) to 4 (always), with higher scores indicating a greater perceived handicap. Total VHI score: 0 to 120

Time frame
At baseline (before surgery) and at 28 days post-surgery

Secondary outcomes

1

Time to nerve identification In Thyroid Surgery

Time to nerve identification after the superior pole vessels are taken down, which starts once the superior pole of the thyroid lobe is taken down and stops once the nerve is visualized and confirmed via nerve monitoring device per surgeon preference. In thyroidectomy, the superior pole vessels (typically the superior thyroid artery and its branches) are often dissected and mobilized before proceeding to the superior laryngeal nerve (SLN) identification. The SLN runs in close proximity to the superior thyroid artery, and thus removing the vessel can help expose the nerve and reduce the risk of injury. Earlier identification allows for protection of the nerve before further dissection.

Time frame
Day of Surgery
2

Visualization Scoring System (VSS) scores

Visualization Scoring System (VSS) is completed during the surgery based on the surgeon's visual assessment using the REVEAL 475 system when viewing the surgical field and the recurrent laryngeal nerve. The REVEAL device and supportive illumination system consists of the TriBeam light source (designed to create a 3-inch spot of white or blue light) and filter-modified surgical loupes. The VSS assessment comprises of a 4-point Likert scale for Nerve Conspicuity (NC) and Branching Delineation of the nerve as compared to its surrounding tissue. NC scores: 1- 'None', 2- 'Weak', 3- 'Clear' and 4- 'Clear and Bright'. Branching Delineation scores: 1- 'None', 2- 'Poorly visible', 3- 'Sufficiently visible' Clear' and 4- 'Excellent visibility'. Total scores: 1 to 32. Higher scores mean better visualization.

Time frame
Day of Surgery
3

NERVE Questionnaire for Surgeons

The NERVE questionnaire, consisting of 9 qualitative questions will be completed at the end of the surgical procedure by the surgeon. The questions measure the surgeon's perceived Confidence, Branching (ability to assess the nerve during the procedure), Discrimination (nerve distinction), Trajectory (ability to assess the nerve trajectory), Depth of penetration (ability to assess the nerve as it goes beyond the surgical surface) Convenience, Ease of use (of Bevonescein), Added value (added benefit/value towards nerve identification and/or localization for this patient) and Satisfaction overall. Possible responses to each question: Very satisfied, Satisfied, Somewhat satisfied, Neither satisfied nor dissatisfied, Somewhat dissatisfied, Dissatisfied, Very dissatisfied. No numerical scoring scale.

Time frame
Day of Surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Matthew Spector

Lead sponsor

University of Pittsburgh

Sponsor institution

Alume Biosciences, Inc.

Collaborator